Get Live Data

focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Scancell Holdings Share Price
  4. Scancell Holdings Share Regulatory News
  5. Investor Update Agenda

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Scancell Holdings Information

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 10.10
High: 10.10
Low: 10.10
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investor Update Agenda

24 Sep 2013 07:00

RNS Number : 6976O
Scancell Holdings Plc
24 September 2013
 



Scancell Holdings Plc

('Scancell')

 

Investor Update Agenda

 

 

Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is to host an Investor Update on Tuesday, 1 October 2013. Details of the event are:

 

Location

FTI Consulting

Holborn Gate

26 Southampton Buildings

London, WC2A 1PB

 

10.45

Registration with refreshments

 

11.00

Introduction

David Evans, Scancell Non-Executive Chairman

 

11.05

Cancer immunotherapy

Prof Peter Stern, Head of the Immunology Group, Paterson Institute for Cancer Research, University

of Manchester

 

11.20

Scancell corporate update

Dr Richard Goodfellow, Joint CEO of Scancell

 

11.30

SCIB1 trial update and introduction to Moditopeâ„¢

Prof Lindy Durrant, Joint CEO of Scancell

 

11.45

Q&A

 

12.00

Interactive panel discussion

Led by Prof Karol Sikora, Dean of Medicine , University of Buckingham; Honorary Consultant Oncologist at Hammersmith Hospital

 

Panellists include:

 

Prof Lindy Durrant,

Prof Peter Stern,

Dr Steve Chan, Consultant Oncologist, City Hospital, Nottingham University

and Prof Christian Ottensmeier, Dept. of Experimental Medicine, University of Southampton

 

12.45

Buffet lunch

 

13.30

Close

 

 

 

For Further Information:

 

Dr Richard Goodfellow, Joint CEO

Professor Lindy Durrant, Joint CEO

Scancell Holdings Plc

Scancell Holdings Plc

+ 44 (0) 20 7831 3113

Camilla Hume/Stephen Keys

Cenkos Securities

+ 44 (0) 20 7397 8900

Mo Noonan/Eleanor Clarke

FTI Consulting

+ 44 (0) 20 7831 3113

 

About Scancell

 

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

 

Scancell's ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

 

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditopeâ„¢ platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADXLFLXKFLBBB
123456789
Date   Source Headline
6th Jul 20167:00 amRNSSCIB1 compelling survival data in melanoma
29th Jun 20164:40 pmRNSSecond Price Monitoring Extn
29th Jun 20164:35 pmRNSPrice Monitoring Extension
17th Jun 20167:00 amRNSSCIB1 Drug Product Supply
2nd Jun 20167:00 amRNSDevelopment of ImmunoBody® Vaccine
18th May 20167:00 amRNSOpens US Headquarters in San Diego
19th Apr 20167:00 amRNSDirector/PDMR Shareholding
11th Apr 20164:11 pmRNSHolding(s) in Company
6th Apr 20167:00 amRNSHolding(s) in Company
4th Apr 201610:17 amRNSResult of the open offer
1st Apr 20167:00 amRNSResult of open offer
23rd Mar 20167:00 amRNSWorld Cancer Vaccine Congress
11th Mar 20167:00 amRNSStrategic collaboration with Karolinska Institutet
11th Mar 20167:00 amRNSPosting of Circular
9th Mar 20162:07 pmRNSPlacing and Open Offer Close
9th Mar 20167:00 amRNSProposed Placing and Open Offer
23rd Feb 20167:00 amRNSPresenting at the Biotech Capital Conference
27th Jan 20169:00 amRNSAmendment to Options
27th Jan 20167:00 amRNSHalf Yearly Report
11th Jan 20167:00 amRNSSCIB1 Early Immune Effect Observed by ImmunTraCkeR
7th Jan 20167:00 amRNSDirectorate Change
5th Jan 20167:00 amRNSKey Moditope paper published in Cancer Research
18th Dec 20157:00 amRNSUS Phase II combination study with SCIB1
20th Oct 20151:05 pmRNSResults of AGM
20th Oct 20157:00 amRNSAGM Business Update
14th Oct 20157:00 amRNSDirectorate Change
6th Oct 20157:00 amRNSSix scientific presentations at PIVAC Conference
18th Sep 20157:00 amRNSFinal Results for the year ended 30 April 2015
16th Sep 20157:00 amRNSImmunoBody presented at Cancer Vaccines Conference
27th Aug 20154:42 pmRNSNotice of AGM
30th Jul 20157:00 amRNSCollaboration with ImmunID
9th Jul 20157:00 amRNSPatient recruitment completed for SCIB1 trial
2nd Jun 20157:00 amRNSSCIB1 data update in resected melanoma patients
17th Apr 20159:00 amRNSPoster on Moditope to be presented at AACR
24th Mar 20154:40 pmRNSSecond Price Monitoring Extn
24th Mar 20154:35 pmRNSPrice Monitoring Extension
24th Mar 20157:00 amRNSSCIB2 synergy with checkpoint inhibitor blockade
12th Jan 20157:00 amRNSPositive SCIB1 Phase 1/2 clinical trial update
15th Dec 20145:22 pmRNSHolding(s) in Company
10th Dec 20147:00 amRNSHalf Yearly Report
22nd Oct 20143:07 pmRNSChange of Registered Office
14th Oct 20146:19 pmRNSResult of AGM
14th Oct 20147:00 amRNSAppointment of Nominated Adviser and Broker
14th Oct 20147:00 amRNSAGM research and development update
30th Sep 20147:00 amRNSPresent at the 14th Annual Biotech in Europe Forum
19th Sep 20149:57 amRNSNotice of AGM
12th Sep 20147:00 amRNSPresenting at Upcoming Scientific Conferences
4th Sep 20147:00 amRNSFinal Results
12th Aug 20147:00 amRNSSynergy of SCIB1 with checkpoint inhibitors
19th Jun 20147:00 amRNSDirector/PDMR Shareholding
123456789

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.